Water-soluble eggshell membrane from Biova supports joint stiffness and performance, says new study

August 6, 2019

Results showed that those with the most physical impairment at baseline experienced the most significant improvement. 

A randomized, double-blind, placebo-controlled study published in the Journal of Food Medicine1 found efficacy in supplementing with a water-soluble eggshell membrane (BiovaFlex) manufactured by Biova LLC (Johnston, IA), to support joint health. In the study, 88 subjects with osteoarthritis were randomized to receive either 450 mg of water-soluble eggshell membrane (WSEM) or placebo, daily, for 12 weeks.

Results showed that in Western Ontario McMaster Osteoarthritis Index (WOMAC) stiffness subscales, subjects taking WSEM saw significant reductions in joint stiffness within five days of supplementation, compared to placebo. Subjects taking WSEM also performed better in a six-minute walk test within five days, compared to placebo. The greatest improvement was seen among subjects who were the most physically impaired at baseline.

“The completion and publication of this study validates the five-day results we saw in our previous joint care clinical and continues to enhance the body of research supporting our proprietary products,” said Pat Schneider, CEO, Biova LLC, in a press release.

References:

1. Hewlings S et al. “A randomized, double-blind, placebo-controlled, prospective clinical trial evaluating water-soluble chicken eggshell membrane for improvement in joint health in adults with knee osteoarthritis.” Journal of Food Medicine, Published online ahead of print August 5, 2019